Key Highlights
- OGEN eased modestly at last closing, trading as a sub-dollar micro-cap.
- Oragenics disclosed a stockholders'-equity deficiency notice from NYSE American on August 28, 2026.
- Its Australian Phase IIa study of ONP-002 for concussion fully activated across three sites on July 7, 2026.
- The company reported a cash position of about $6.1 million at the end of the first quarter of 2026.
Once known for early-stage antibiotics and probiotics work, Oragenics Inc (NYSE American:OGEN) has reinvented itself as a neuroscience-focused developer built around intranasal drug delivery for brain injury. The company, listed on NYSE American under the ticker OGEN, is a sub-dollar micro-cap advancing a mid-stage concussion trial abroad while wrestling with a listing-compliance question at home. A modest pullback in the shares put focus on levels and catalysts, though the near-term story is really about clinical execution and a shrinking cash cushion.
Company and Latest Development
Oragenics is developing ONP-002, an intranasally administered neurosteroid intended to treat concussion and traumatic brain injury, using its proprietary intranasal delivery approach. Through 2026 the company has steadily advanced a Phase IIa study in Australia. It dosed its first patient in April 2026, activated additional sites through the spring, and on July 7, 2026 announced full activation of its Australian trial network, with all three sites enrolling and, it said, no serious adverse events reported to that point. Oragenics has also signaled pipeline ambitions beyond ONP-002, including a May 2026 letter of intent to license a technology aimed at TBI-induced systemic inflammation.
What Is Driving Attention Around OGEN?
The modest decline does not tie to a single verifiable same-day event. As a low-priced micro-cap, OGEN trades with elevated Volatility on limited volume. The more material development is corporate rather than price-driven: on August 28, 2026, Oragenics disclosed that it had received a deficiency notice from NYSE American for failing to meet a stockholders' Equity listing standard, with a cure period to submit a compliance plan. That listing overhang, set against ongoing clinical progress, is the backdrop investors are weighing.
Key Numbers and Company Position
Oragenics reported a cash position of about $6.1 million at the end of the first quarter of 2026. Its 2025 Annual Report highlighted a $16.5 million Capital raise during that year and an 11% reduction in operating expenses. The current Phase IIa study is designed to enroll roughly 40 patients, dosing within a short window after concussion across the activated Australian sites. Market data show OGEN as a sub-dollar stock with a small market capitalization; the recently disclosed shortfall in stockholders' equity is the specific metric behind the NYSE American deficiency notice.
What Could Come Next?
The key near-term catalysts are clinical and regulatory. Investors may watch enrollment progress and any interim safety or efficacy readouts from the ONP-002 Phase IIa study, along with the outcome of the NYSE American compliance process and whether Oragenics can regain or maintain its listing. Any completion of the licensing letter of intent, new financings, or updates to cash runway would also be closely followed given the modest balance.
Risks to Watch
The risks are substantial. Oragenics is a pre-revenue clinical-stage company dependent on trial success that is far from assured, and its cash position is small relative to development costs, implying likely additional dilution. The NYSE American deficiency notice raises the possibility of delisting if a compliance plan is not accepted or executed. Sub-dollar micro-cap trading brings wide swings, and competition and regulatory uncertainty in neuroscience remain significant.
Clinical Momentum Against a Listing Overhang
Oragenics moves through late 2026 balancing genuine clinical momentum in its ONP-002 concussion program against a listing-compliance challenge and a limited cash runway. Trial enrollment and any early data, the resolution of the NYSE American equity deficiency, and future financing steps are likely to be the developments investors monitor most closely.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...